$ELAB – Tiny Float, Multiple Growth Engines

With an extremely low float around 500k shares, it has the potential to make a significant move if volume steps in. This could be the next big one to watch. What Is $ELAB Actually Doing? PMGC Holdings Inc. ($ELAB) (formerly Elevai Labs) has quietly transformed from a skincare company into a diversified holding company with exposure to several high-growth sectors — all packed into a tiny float. Their portfolio includes: • NorthStrive Biosciences – developing next-gen biotech and therapeutic assets, including obesity and mitochondrial programs. • Manufacturing & industrial subsidiaries – precision machining and packaging operations, adding real, tangible business lines. • PMGC Capital – an investment arm targeting high-growth tech and energy opportunities, including micro modular reactor exposure. • AI-driven research division focused on drug discovery and advanced biopharma pipelines. This is not a one-product story. It’s multiple asymmetric upside bets under one ticker. Upcoming & Recent Potential Catalysts for $ELAB: • Phase III AI Drug Validation (NorthStrive) – advancing toward meaningful scientific validation, which could significantly de-risk the biotech side of the business. • AS9100 Aerospace Certification – opens the door to defense, aerospace, and high-spec industrial contracts, a major credibility upgrade for the manufacturing arm. Strategic exposure to advanced energy and nuclear technology via PMGC Capital, positioning ELAB in next-generation energy infrastructure. • Ongoing acquisition roll-ups – expanding the company’s operational footprint and revenue base instead of relying on a single asset. When you combine multiple growth verticals, stacked catalysts, and a very small float, you get a setup where any positive development can move the stock quickly. Supply is limited, and momentum is already building up fast. Do your own DD. Goodluck!